Wedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $44
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Wedbush analyst Laura Chico maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $42 to $44.
Wedbush analyst Laura Chico maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $42 to $44.